| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.28 | 1e-12 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-08 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | -0.2 | 3e-07 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.22 | 3e-07 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.21 | 1e-06 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.18 | 3e-06 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.19 | 6e-06 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.18 | 6e-06 |